Navigation Links
Yves Saint Laurent Eyewear

ProductsYves Saint Laurent Eyewear
Company Safilo Group
Item Yves Saint Laurent Eyewear
Features 
  • The ladies' sunglasses range represents a constant for sophistication and elegance. Whether it's vintage or strictly contemporary, the styles are expansive and expressive. Luxurious details such as the metallic motif are inspired by the Vincennes bag or the engraved Yves Saint Laurent plate attached to the legs. The colour ranges are highly sought-after and give the models that extra finish.
  • The sunglasses range for men stands out with its truly vintage-inspired details. The playful combination of materials, the use of the perforated bridge, the metal-framed lenses, and even the name of the designer engraved on the upper part of the bridge all combine to create a highly unique range that is instantly recognisable by the discreet logo by Cassandre.
  • The optical range is particularly innovative, with the use of details borrowed directly from the house's own collections and enhanced by the interplay of colour. The men's frames take up the retro-inspired theme of the sunglasses range, creating an unfussy, discreet yet essential look.
Description Sophisticated and highly sought-after, the new YVES SAINT LAURENT collection of sunglasses and frames brings together elements of the very latest men's and ladies' collections with timeless sources of inspiration to mirror the exquisitely refined personality of the French design house.
Info Safilo Group
Customer Service: 049-6985111
Web site: http://www.safilo.com/home-usa.php

Related medicine products :

1. 72 Frame Eyewear Tower - Silver
2. QualCraft™ Radiation Protection Eyewear -- Metal
3. Radiation Protection Eyewear
4. Astro Flex Splash Radiation Protection Eyewear With Shield
5. Clip On Protective Eyewear
6. Standard Protective Eyewear
7. Wrap Around Glasses Protective Eyewear
8. Wrap Around Goggles Protective Eyewear
9. MicroLite Plus Leaded Eyewear Silver
10. Alexander McQueen Eyewear Collection
11. Gucci Eyewear and Sunglasses
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish.
Narrow 4 mm long smooth platform. Serrated handle with polished finish.
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish.
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products:
(Date:10/7/2008)...han 4,300 Activity Bags Donated to Area Youth in H...nio, HOUSTON, Oct. 7 /PRNewswire/ -- Carlson Hote...ether to provide more than 1,900 activity bags,to ... area. The tote bags,contained a fun activity book...., (Photo: http://www.newscom.com/cgi-bin/prnh/2...
(Date:10/7/2008)...N, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Majesco ...ive provider of video games for the mass,market, t...matum 2009 has,gone gold and is scheduled to ship ... of its kind to integrate a celebrity fitness trai... life coach on the popular television,series "The ...
(Date:10/7/2008)...Y, France, October 7 /PRNewswire-FirstCall/ -- Sta...red into an exclusive agreement with,Catalent for ...line,autoinjector, ADREFLEX(R), co-developed and c...LC., ADREFLEX(R) consists of a syringe pre-filled...t and paediatric use (0.3 and 0.15 mg), in an,auto...
(Date:10/7/2008)...LAND, Oct. 7 /PRNewswire/ -- Cleveland Medical Dev... $1.23 million in NIH SBIR,FastTrack funding from ...une(TM), a system to augment stimulator programmin...arkinson,s disease (PD). CleveMed is,collaborating...storation of,the Cleveland Clinic Foundation, a wo...
Breaking Medicine News(10 mins):Health News:Carlson Hotels Worldwide Partners With the American Red Cross in Texas to Provide Relief for Children Affected by Hurricane Ike 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 3Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinson's Disease 2
...er of the Bernhard Nocht Institute for Tropical Me...arial //parasite avoids the immune system by killi...s known that after infecting man, malarial parasit...ct the red blood cells, but it was not known how t...
...sity, University of California-Davis and Justus-Li...treatments //could be possible for autism and Park...focused their attention despite being distracted u...t a measure of cognitive deficit in mice that is r...
... are born infected with human cytomegalovirus, or ...anent disabilities due to the virus – almost one a...oss, vision loss, mental disability, a lack of coo... for Disease Control and Prevention, CMV is as com...
...from infection causing agents. Regulatory T-cells,...s of life itself to recognize// the invaders and d...ese cells seem to protect certain bacteria, viruse...ical college of Georgia, studied the T-cells in th...
Other Medicine News:Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 3Health News:Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined 2Health News:Regulatory T-cells – Protector or Cause of Diseases 2Health News:Regulatory T-cells – Protector or Cause of Diseases 3
(Date:10/6/2008)...G, Pa., Oct. 6 /- Genaera,C...om its second Phase 1,clinical trial of trodusquem...the treatment of type 2 diabetes and obesity. MSI-...lecular target that controls the function,of both ...se and decrease,appetite. In the study, MSI-1436 w...
(Date:10/6/2008)...erence Call Scheduled for 9:00 AM ET Today -, SEA...rporation (Nasdaq:,DNDN) announced today that it h...hase 3, randomized, double-blind, placebo-controll...ma Treatment, also known as D9902B),clinical trial...,investigational active cellular immunotherapy PRO...
(Date:10/6/2008)... /- Dendreon Corporation (N...nday, October 6, 2008 at 9:00 AM,ET (6:00 AM PT) t...s IMPACT,(IMmunotherapy for Prostate AdenoCarcinom...of PROVENGE(R) (sipuleucel-T), the Company,s inves...reatment of advanced prostate,cancer., Those i...
(Date:10/5/2008)...ed in New England Journal of Medicine reaffirm,wel...e of SPIRIVA(R),HandiHaler(R), RIDGEFIELD, Conn.,...he,UPLIFT (Understanding Potential Long-term Impac... SPIRIVA(R) HandiHaler(R) (tiotropium bromide,inha...ction for up to 4,years as measured by FEV(1) (p<0...
Breaking Medicine Technology:Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 2Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 3Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 4Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 5Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years 6RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 1RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 2RoundTable Healthcare Partners Closes Sale of MedAssist Holding Inc to Firstsource Solutions Limited 939 3Center for Poverty Research to study senior hunger in America 2387 1Center for Poverty Research to study senior hunger in America 2387 2Connecticut Catholic Conference Wrong to Allow Plan B in Catholic Hospitals 2384 1Connecticut Catholic Conference Wrong to Allow Plan B in Catholic Hospitals 2384 2American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification 28TAN 29 Act 2380 1American Academy of Dermatology Association Commends President Bush for Signing Tanning Accountability and Notification 28TAN 29 Act 2380 2
...e/ -- A nationally renowned,cancer researcher affi...nted a novel study design concept called a Complet...e new agent development.,Studies utilizing this de...work,s innovative Translational Oncology Program (...e trials in a community,setting. These types of tr...
...nted at American Society of,Clinical Oncology (ASC...Newswire-FirstCall/ -- Medarex, Inc.,and Bristol-M...ultiple clinical studies of ipilimumab (MDX-010), ...h advanced melanoma.,The results demonstrated an a...melanoma either as a monotherapy or in combination...
Other Medicine Technology:Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 2Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 3Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 4Study Shows Advantages of Complete Phase Ib Trial Over Separate,Phase I Trials 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 2Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 3Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 4Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 5Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 6Data Demonstrated Metastatic Melanoma Response to Investigational,Immunotherapy Ipilimumab 7